A single next generation sequencing assay for detection of driver mutations, rearrangements and copy number abnormalities in plasma cell dyscrasias - Top-Institutions - MDSpire

A single next generation sequencing assay for detection of driver mutations, rearrangements and copy number abnormalities in plasma cell dyscrasias

  • By

  • Cecilia Bonolo de Campos

  • Daniela Trujillo

  • James Smadbeck

  • Mariano Arribas

  • Hongwei Tang

  • Neeraj Sharma

  • Gregory J. Ahmann

  • Shaji K. Kumar

  • A. Keith Stewart

  • Rafael Fonseca

  • P. Leif Bergsagel

  • Yan W. Asmann

  • Linda B. Baughn

  • Esteban Braggio

  • March 28, 2026

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Oncology
    • Genomic Medicine

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology
    • Cancer Genomics

  • #3

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Genomic Medicine

  • #4

    University of Arkansas for Medical Sciences (UAMS)
    University of Arkansas for Medical Sciences (UAMS)

    Little Rock, AR

    Key Differentiators

    • Hematology
    • Oncology
    • Genomic Research

  • #5

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Hematology
    • Oncology
    • Genomic Medicine

Original Source(s)

A single next generation sequencing assay for detection of driver mutations, rearrangements and copy number abnormalities in plasma cell dyscrasias

  • by Cecilia Bonolo de Campos, Daniela Trujillo, James Smadbeck, Mariano Arribas, Hongwei Tang, Neeraj Sharma, Gregory J. Ahmann, Shaji K. Kumar, A. Keith Stewart, Rafael Fonseca, P. Leif Bergsagel, Yan W. Asmann, Linda B. Baughn, Esteban Braggio

  • March 28, 2026

Related Content

This Week’s Biopharma News: Amgen Deepens US Manufacturing Push

The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production

  • May 12, 2026

  • 7 min
Patient Awareness, Attitudes, and Preventive Practices Related to Venous Thromboembolism in Multiple Myeloma: A Cross-Sectional Analysis

Differential expression of immune activation markers in T cells from patients with multiple myeloma